公开(公告)号：US20190048098A1

公开(公告)日：2019-02-14

申请号：US16061903

申请日：2016-12-15

Applicant: Biogen MA Inc.

Inventor： Martin Preyer

IPC: C07K16/46 ,  C07K16/28 ,  C07K14/765 ,  C07K16/32

Abstract: Provided herein are solutions to the heavy and light chain mispairing problems in bispecific antibodies. One part of the solution involves Fc regions that are engineered in their CH3 domains by lysine repositioning to drive heterodimerization of the two heavy chains of the bispecific antibody. The second part of the solution involves a modification of one of the two Fab arms of the bispecific antibody so as to prevent mispairing of light chains in the bispecific antibody. Specifically, the CH1 and CL domains of one of the Fab arms of the bispecific antibody are substituted with an IgE CH2 domain or an IgM CH2 domain.

公开(公告)号：US11447575B2

公开(公告)日：2022-09-20

申请号：US16061903

申请日：2016-12-15

Applicant: Biogen MA Inc.

Inventor： Martin Preyer

IPC: C07K16/46 ,  C07K16/28 ,  A61K39/395 ,  C07K14/765 ,  C07K16/32

Abstract: Provided herein is a platform technology for the generation of properly paired bispecific antibodies. Some of the antibodies generated have Fc region modifications, in particular in their CH3 domains by lysine repositioning to drive heterodimerization of the two heavy chains of the bispecific antibody. Some of the antibodies generated have Fab arm modifications to prevent mispairing of light chains. Specifically, the CH1 and CL domains of one of the Fab arms of the bispecific antibody are substituted with an IgE CH2 domain or an IgM CH2 domain.

公开(公告)号：US20170362324A1

公开(公告)日：2017-12-21

申请号：US15510422

申请日：2015-09-11

Applicant: Biogen MA Inc.

Inventor： Thomas Owen Cameron ,  Michael Adam Crackower ,  Brian M. Dolinski ,  Karl J.M. Hanf ,  Amy Theresa McCurley ,  Nels Eric Pederson ,  Martin Preyer ,  Fang Qian ,  Shelia M. Violette ,  Paul Henry Weinreb

IPC: C07K16/28

CPC classification number: C07K16/2839 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Humanized antibodies and antibody fragments that bind to αvβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent αvβ5-mediated diseases.